达雷妥尤单抗联合硼替佐米基础化疗方案治疗mSMART高危多发性骨髓瘤患者的疗效OA

Objective To analyze the effect of basic chemotherapy regimen of daratumumab combined with bortezomib in stratification for myeloma and risk-adapted therapy(mSMART)patients with high-risk multiple myeloma.Methods Clinical data of 87 high-risk multiple myeloma patients with mSMART score≥4 were retrospectively analyzed,and according to therapeutic regimens,they were divided into control group(60 cases,receiving bortezomib basic chemotherapy regimen)or observation group(27 cases,receiving daratumumab combined with bortezomib basic chemotherapy regimen).The pre-and post-treatment Numeric Rating Scale(NRS)score for pain,Karnofsky Perfomance Scale(KPS)score,CD4+/CD8+ratio,and CD4+and CD3+levels,as well as post-treatment clinical efficacy,adverse reactions,and prognosis were compared between the two groups.Results After treatment,the NRS scores for pain in the two groups were lower than those before treatment,and the KPS score,CD4+/CD8+ratio,and CD4+and CD3+levels were higher than those before treatment,and the NRS score for pain in the observation group was lower than that in the control group,whereas the KPS score,CD4+/CD8+ratio,and CD4+and CD3+levels were higher than those in the control group(P<0.05).The total clinical effective rate of the observation group was higher than that of the control group(P<0.05).During treatment,there was no statistically significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).At 2 years of follow-up,the survival rate of the observation group was higher than that of the control group(P<0.05).Conclusion Basic chemotherapy regimen of daratumumab combined with bortezomib for the treatment of mSMART patients with high-risk multiple myeloma is superior to bortezomib basic chemotherapy regimen,which can reduce pain degree,improve immune function and quality of life,improve short-term survival rate of patients,exerting a good safety.